Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M GREENAWAY

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer|November 26, 1999
Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesisJ R Burgess, T M Greenaway, V Parameswaran, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|December 1, 1992
Increased gluconeogenesis in hepatocytes from GTG-obese mice is insensitive to inhibition by insulinT M Greenaway, G J Cooney, S C Blair, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1996
Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindredJ R Burgess, J J Shepherd, V Parameswaran, et al.
The Journal of Clinical Endocrinology and Metabolism|May 1, 1996
Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance patternJ R Burgess, J J Shepherd, V Parameswaran, et al.
Archives of Surgery (Chicago, Ill. : 1960)|March 4, 1998
The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1J R Burgess, R David, V Parameswaran, et al.
Archives of Surgery (Chicago, Ill. : 1960)|October 16, 1999
Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomyJ R Burgess, R David, T M Greenaway, et al.
The American Journal of Medicine|May 1, 1996
Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindredJ R Burgess, J J Shepherd, V Parameswaran, et al.
European Journal of Clinical Nutrition|February 7, 2003
A randomized controlled trial of phytoestrogen supplementation, growth and bone turnover in adolescent malesG Jones, T Dwyer, K Hynes, et al.
The Medical Journal of Australia|June 17, 1996
Effective control of bone pain by octreotide in a patient with metastatic gastrinomaJ R Burgess, J J Shepherd, F J Murton, et al.
The Medical Journal of Australia|May 18, 1999
Management of insulin-treated diabetes in TasmaniaD J McCarty, T M Greenaway, M C Kamp, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer|November 26, 1999
Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesisJ R Burgess, T M Greenaway, V Parameswaran, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|December 1, 1992
Increased gluconeogenesis in hepatocytes from GTG-obese mice is insensitive to inhibition by insulinT M Greenaway, G J Cooney, S C Blair, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1996
Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindredJ R Burgess, J J Shepherd, V Parameswaran, et al.
The Journal of Clinical Endocrinology and Metabolism|May 1, 1996
Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance patternJ R Burgess, J J Shepherd, V Parameswaran, et al.
Archives of Surgery (Chicago, Ill. : 1960)|March 4, 1998
The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1J R Burgess, R David, V Parameswaran, et al.
Archives of Surgery (Chicago, Ill. : 1960)|October 16, 1999
Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomyJ R Burgess, R David, T M Greenaway, et al.
The American Journal of Medicine|May 1, 1996
Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindredJ R Burgess, J J Shepherd, V Parameswaran, et al.
European Journal of Clinical Nutrition|February 7, 2003
A randomized controlled trial of phytoestrogen supplementation, growth and bone turnover in adolescent malesG Jones, T Dwyer, K Hynes, et al.
The Medical Journal of Australia|June 17, 1996
Effective control of bone pain by octreotide in a patient with metastatic gastrinomaJ R Burgess, J J Shepherd, F J Murton, et al.
The Medical Journal of Australia|May 18, 1999
Management of insulin-treated diabetes in TasmaniaD J McCarty, T M Greenaway, M C Kamp, et al.
Pageof 4